Beiki O, Frumento P, Bottai M, Manoucherhinia A, Hillert J. Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: A nationwide population-based cohort study in Sweden. JAMA Neurol. 2019;76:665–71. https://doi.org/10.1001/jamaneurol.2019.0330.

Article  PubMed  PubMed Central  Google Scholar 

Abdelrahman A, Alvarez E. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies. Neurol Clin. 2024;42(1):115–35. https://doi.org/10.1016/j.ncl.2023.08.002.

Article  PubMed  Google Scholar 

Hartung DM. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther Adv Neurol Disord. 2021;14:1756286420987031.

Article  PubMed  PubMed Central  Google Scholar 

Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020;7(9):1477–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, et al. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Mult Scler 2022;28(9):1424–1456. https://doi.org/10.1177/13524585211069068

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77:1079–88. https://doi.org/10.1001/jamaneurol.2020.2581.

Article  PubMed  Google Scholar 

Chaudhry F, Bulka H, Rathnam AS, Said OM, Lin J, Lorigan H, et al. COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020;418:117147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salter AGA. COViMS registry and UKMSR. Presented at 8th Joint European Committee for Treatment and Research in Multiple Sclerosis-Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) 2020; Washington DC, United States

Langer-Gould A, Smith JB, Li BH; KPSC MS Specialist Group. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol 2021;8(4):938–943. https://doi.org/10.1002/acn3.51342

Signori A, Schiavetti I, Gallo F, Sormani MP. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol. 2015;22(6):960–6. https://doi.org/10.1111/ene.12690.

Article  CAS  PubMed  Google Scholar 

Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother. 2021;21(3):353–64. https://doi.org/10.1080/14737175.2021.1886082.

Article  CAS  PubMed  Google Scholar 

Macaron G, Larochelle C, Arbour N, Galmard M, Girard JM, Prat A, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol. 2023;14:1197212. https://doi.org/10.3389/fneur.2023.1197212.

Article  PubMed  PubMed Central  Google Scholar 

Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol. 2017;8:577. https://doi.org/10.3389/fneur.2017.00577.

Article  PubMed  PubMed Central  Google Scholar 

Jalaleddini K, Bermel RA, Talente B, Weinstein D, Qureshi F, Rasmussen M, et al. A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis. Mult Scler. 2024;30(3):432–42. https://doi.org/10.1177/13524585241227372.

Article  PubMed  Google Scholar 

Zhang Y, Salter A, Jin S, Culpepper WJ 2nd, Cutter GR, Wallin M, et al. Disease-modifying therapy prescription patterns in people with multiple sclerosis by age. Ther Adv Neurol Disord. 2021;14:17562864211006500. https://doi.org/10.1177/17562864211006499.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cisternas M, Bartolome L, Gitar B, Hulbert E, Trenz H, Patel V, et al. Health care resource utilization and disease modifying treatment use in multiple sclerosis patients by age and insurance type. Curr Med Res Opin. 2021;37(4):597–604. https://doi.org/10.1080/03007995.2021.1885367.

Article  PubMed  Google Scholar 

Goereci Y, Ellenberger D, Rommer P, Dunkl V, Golla H, Zettl U, et al. Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry. J Neurol. 2024;271(6):3409–16. https://doi.org/10.1007/s00415-024-12286-4.

Article  PubMed  PubMed Central  Google Scholar 

McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JJ, Miller D. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Mult Scler. 2020;26(12):1581–9. https://doi.org/10.1177/1352458519867314.

Article  PubMed  Google Scholar 

Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147–61. https://doi.org/10.1093/brain/awac016.

Article  PubMed  PubMed Central  Google Scholar 

Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020;77(9):1132–40. https://doi.org/10.1001/jamaneurol.2020.1568.

Article  PubMed  Google Scholar 

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al; MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 2019;321(2):175–187. https://doi.org/10.1001/jama.2018.20588

Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019;76(5):536–41. https://doi.org/10.1001/jamaneurol.2018.4905.

Article  PubMed  PubMed Central  Google Scholar 

Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Danny B, Christensen JR, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. Neurol. 2020;95(8):e1041–51. https://doi.org/10.1212/WNL.0000000000010135.

Article  CAS  Google Scholar 

He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al; MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020;19(4):307–316. https://doi.org/10.1016/S1474-4422(20)30067-3

Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021;78(10):1197–204. https://doi.org/10.1001/jamaneurol.2021.2738.

Article  PubMed  Google Scholar 

Lewis S (Ed.) Monitoring, Switching, and Stopping MS Disease-Modifying Therapies. Robert Gross and John Corboy. Continuum: Lifelong Learning in Neurology. American Academy of Neurology: June 2019; 25(3):715–735.

Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382–94. https://doi.org/10.1007/s00415-022-11193-w.

Article  PubMed  PubMed Central  Google Scholar 

Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37–51. https://doi.org/10.1038/s41582-020-00427-y.

Article  PubMed  Google Scholar 

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, et al; CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurol 2017;89(11):1117–1126. https://doi.org/10.1212/WNL.0000000000004354

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, et al. Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Ther Adv Neurol Disord 2023;16:17562864231200627. https://doi.org/10.1177/17562864231200627

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023;29(6):719–30. https://doi.org/10.1177/13524585231161494.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rush CA, Atkins HL, Freedman MS. Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019;9(3):a029082. https://doi.org/10.1101/cshperspect.a029082.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJ, Segal BM. Ageing and multiple sclerosis. Lancet Neurol. 2023;22:66–77. https://doi.org/10.1016/S1474-4422(22)00184-3.

Article  PubMed  Google Scholar 

Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. Exp Gerontol. 2019;124:110632.